Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Arena Pharmaceuticals |
---|---|
Information provided by: | Arena Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00828581 |
The purpose of this study is to evaluate the PK properties of lorcaserin in obese or overweight elderly subjects.
Condition | Intervention | Phase |
---|---|---|
Obesity |
Drug: lorcaserin |
Phase I |
Study Type: | Interventional |
Study Design: | Open Label, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects |
Enrollment: | 24 |
Study Start Date: | October 2008 |
Study Completion Date: | December 2008 |
Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Lorcaserin: Experimental | Drug: lorcaserin |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
History of any of the following cardiovascular conditions:
United States, New Jersey | |
CRI Worldwide - Lourdes Hospital | |
Willingboro, New Jersey, United States, 08046 |
Investigator: | Christen Anderson, MD, PhD | Arena Pharmaceuticals |
Responsible Party: | Arena Pharmaceuticals, Inc. ( Christen Anderson, MD, PhD ) |
Study ID Numbers: | APD356-018 |
Study First Received: | January 22, 2009 |
Last Updated: | January 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00828581 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Body Weight Signs and Symptoms Obesity |
Nutrition Disorders Overnutrition Overweight |
Body Weight Signs and Symptoms Obesity |
Nutrition Disorders Overweight Overnutrition |